Entity family

Browse funders

Organisations named as supporting, sponsoring, or funding research. Examples include Wellcome, NIHR, research councils.

5,089articles mentioning funders

9,137funder mentions

3,238distinct funders extracted

0%of mentions human-reviewed

Filter articles

JournalContent resourceEvidence policyAutomated confidence floorArticles per pageReset filters

“Reviewed + threshold” includes every confirmed correction plus unreviewed proposals at or above the selected model score.

All extracted funders

Showing 1,081–1,140 of 3,238, ordered by supporting articles. Choose a funder to see its evidence.

Clinical Events Committee1 Clinical Trial Registry-India1 Clinical Trials Ontario Research Ethics Board1 Clinical Trials Registry1 Clinical Trials Registry NCT064716081 Clinical Trials Registry of India1 Clinical Trials Registry-India1 ClinicalTrials gov. NCT047970131 ClinicalTrials. gov1 ClinicalTrials.gov NCT045855811 ClinicalTrials.gov NCT057782141 ClinicalTrials.gov NCT059099821 ClinicalTrials.gov NCT064215321 ClinicalTrials.gov NCT070528901 ClinicalTrials.gov Registry1 ClinicalTrialsRegister.eu1 Clinicaltrials.gov NCT063024001 Clinigen Limited1 CoImpact1 CoMSA1 CoSRH1 Coalition1 Coalition for National Trauma Research1 Coca-Cola1 Cochrane Central Database1 Cochrane Central Register of Clinical Trials1 Cochrane Central Registry1 Cochrane Controlled Trials Register1 Cochrane Pregnancy and Childbirth Register1 Cochrane Rapid Review Methods Group1 Cochrane network1 Cochrane-CENTRAL1 College of Sexual and Reproductive Healthcare1 Colonial Medical Service1 Colt Foundation1 Comisión Interministerial de Precios de Medicamentos1 Comitato Etico Campania 21 Comité de Protection des Personnes Est1 Comité de Protection des Personnes Ile de France I1 Comité de Protection des Personnes Ile de France XI1 Comité de Protection des Personnes Nord-Ouest II1 Comité de Protection des Personnes Ouest V1 Comité de Protection des Personnes Ouest VI1 Comité de Protection des Personnes Sud-Est VI1 Comité de protection des personnes Est III1 Comité de protection des personnes Ile de France IV1 Comité de protection des personnes Nord Ouest I1 Comité de protection des personnes Île-de-France II1 Comité de Ética en Investigación Biomédica1 Comités de Protection des Personnes Ouest-I Ethics Committee1 Commission cantonale d’éthique de la recherche1 Committee of Hospital Universitario 12 de Octubre1 Community Interest Company1 Community Voluntary Services1 Company Chemists’ Association1 Compass Therapeutics1 Compassion in Dying1 Conexus Nuclear Inc.1 Confederación Sudamericana de Fútbol1 Confederation of Sports1

View all 3,238 funders on one page

Articles mentioning funders

5,089 articles · page 119 of 425

599 The MATRiX trial: a multicenter, randomized, phase II study of ATR inhibition (via tuvusertib) with or without avelumab in patients with advanced anti-PD-(L)1-refractory merkel cell carcinoma

jitc · abstract · 2025-11-04 · 2 matching annotations

77.4%

Mark Foundation for Cancer Research EMD Serono tuvusertib ceralasertib durvalumab avelumab AZD6738

…ease. EDDOP Leadership Award-P30 Administrative Supplement, the Mark Foundation for Cancer Research, the Kelsey Dickson Team Science Courage Research Team Award, a…

626 Real-time multidimensional prognostic model for immuno-chemotherapy in advanced biliary tract cancer: an observational multicohort study

jitc · abstract · 2025-11-04 · 2 matching annotations

90.2%

ClinicalTrials.gov immune checkpoint inhibitors chemotherapy immuno-chemotherapy Zhongda Hospital Affiliated to Southeast University BTC advanced biliary tract cancer

…otocol is detailed in figure 1, and the study was registered on ClinicalTrials.gov (NCT06849193).Results 2314 patients were included (841 in the d…

656 Focused ultrasound thermal ablation and CD40 agonist drive tumor regression and immunologic memory via innate and adaptive reprogramming in breast cancer

jitc · abstract · 2025-11-04 · 2 matching annotations

85.3%

NIH DP5OD031846 DOD BCRP Era of Hope Scholar Award University of Virginia cancer breast cancer BC αCD40

…T-FUS+αCD40 setting.Acknowledgements This work was supported by NIH DP5OD031846 and T32CA009109, DOD BCRP Era of Hope Scholar Award, Wallace H.…

666 Combinatorial therapy of intratumoral adjuvant and systemic PD-1 inhibitor shows synergistic effect in head and neck squamous cell carcinoma

jitc · abstract · 2025-11-04 · 2 matching annotations

91.0%

German Research Foundation Walter Benjamin Fellowship head and neck squamous cell carcinoma pembrolizumab Head and neck squamous cell carcinoma (HNSCC)University of California San Diego Nivolumab Gleiberman Head and Neck Cancer Center cetuximab PD-1i+2 more

…nodes.Acknowledgements The author acknowledges support from the German Research Foundation through a Walter Benjamin Fellowship, and the Gleiberman Head a…

718 Global quantitative patient chart review of multidisciplinary team (MDT) care and treatment use in early-stage non-small-cell lung cancer (NSCLC)

jitc · abstract · 2025-11-04 · 2 matching annotations

96.2%

AstraZeneca neoadjuvant treatment chemoradiotherapy stage I-IIIB NSCLC consolidation therapy adjuvant therapy neoadjuvant therapy surgery NSCLC

…us community settings.Acknowledgements This study was funded by AstraZeneca. Medical writing support for the development of this abstract, …

74 Automated co-detection of small RNAs, RNAs and proteins with Roche DISCOVERY™ ULTRA

jitc · abstract · 2025-11-04 · 2 matching annotations

91.0%

FDA EMA neurodegenerative/neuromuscular disorders rare diseases FDA Roche DISCOVERY™ ULTRA System

… and EMA, and many more are in clinical phase I-III trials. The FDA has issued recommendations to generate nonclinical biodistribut…

857 Commandeering T cell fates and adoptive T cell therapeutic outcomes in solid tumors using cytokines and de novo engineered mimetics

jitc · abstract · 2025-11-04 · 2 matching annotations

85.6%

Rachel Lynn Henley Foundation Hopes and Smiles For Children Foundation melanoma National Institutes of Health Cancer neuroblastoma head and neck cancer glioma sarcoma refractory solid tumors+1 more

…unding from the Pediatric Cancer Research Foundation to SS, the Rachel Lynn Henley Foundation to VK, the Hopes and Smiles For Children Foundation to VK, In C…

888 Composition of the natural immunomodulatory medicinal products obtained from bovine thymus

jitc · abstract · 2025-11-04 · 2 matching annotations

85.0%

European Union Lubelskie Regional Programme RPLU Thymomodulin supportive therapy Thymus extract immune dysregulation Thymosin reactivated human alphaherpesvirus1 infections ThymicPeptides

… thymus extract.Acknowledgements This work was supported by the European Union from the Lubelskie Regional Programme RPLU.01.02.00-06-0015/20.…

930 Discovery of immunogenic neo-peptides from actionable chimeric RNAs to develop personalized vaccines for breast cancer treatment

jitc · abstract · 2025-11-04 · 2 matching annotations

80.1%

World Health Organization Breast cancer CDK4/6 inhibitors endocrine therapy CDK 4/6 inhibitors XenoSTART CDK4/6

…ncer burden growing, amidst mounting need for services. Geneva: World Health Organization; 2024 Feb 1.Hernandez T, Kneifel D, Simonson A, Flores J, Quick…

931 Discovery of immunogenic neopeptides from actionable RNA fusion ESR1-PRKN for developing cancer vaccines

jitc · abstract · 2025-11-04 · 2 matching annotations

82.5%

World Health Organization breast cancer CDK4/6 inhibitors endocrine therapy CDK 4/6 inhibitors XenoSTART CDK4/6

…ncer burden growing, amidst mounting need for services. Geneva: World Health Organization; 2024 Feb 1,Hernandez T, Kneifel D, Simonson A, Flores J, Quick…

94 Decoding immune suppression in Merkel cell carcinoma through integrated spatial transcriptomics and multiplex proteomics

jitc · abstract · 2025-11-04 · 2 matching annotations

81.3%

National Institutes of Health NIH The Ohio State University Comprehensive Cancer Center Merkel cell carcinoma OSUCCC Pelotonia Institute for Immuno-Oncology MCC anti-PD-1/PD-L1 therapies

…o State University Comprehensive Cancer Center (OSUCCC) and the National Institutes of Health (NIH) under grant P30CA016058. This research was made possible …

964 Development of conditional T cell engagers (INDUCER™ molecules) with a highly effective masking approach to reduce dose-limiting cytokine release and off-target peripheral toxicity

jitc · abstract · 2025-11-04 · 2 matching annotations

79.7%

NIH U.S. Department of Agriculture hematological malignancies solid tumors Discovery Life Sciences NeoSome Life Sciences Charles River Laboratories BioIVT INDUCER™ molecules TCEs

…ons and standards of the U.S. Department of Agriculture and the NIH at Charles River Laboratories or NeoSome Life Sciences with the…